ANAPTYSBIO
AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturali... zing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.
ANAPTYSBIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.anaptysbio.com
Total Employee:
51+
Status:
Active
Contact:
(858) 362-6295
Email Addresses:
[email protected]
Total Funding:
85.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Domain Not Resolving Wordpress Plugins Sitelinks Search Box
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Allakos
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Ophidion
Ophidion is a biotechnology company that delivers a central nervous system therapeutics to targeted sites in the brain.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series D - AnaptysBio
Biotechnology Value Fund
Biotechnology Value Fund investment in Series D - AnaptysBio
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - AnaptysBio
BioMed Ventures
BioMed Ventures investment in Series D - AnaptysBio
Cormorant Asset Management
Cormorant Asset Management investment in Series D - AnaptysBio
Novo Holdings
Novo Holdings investment in Series B - AnaptysBio
Avalon Ventures
Avalon Ventures investment in Series B - AnaptysBio
Alloy Ventures
Alloy Ventures investment in Series B - AnaptysBio
Numenor Ventures
Numenor Ventures investment in Series B - AnaptysBio
WS Investments
WS Investments investment in Series B - AnaptysBio
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-31 | AnaptysBio Appoints Paul Lizzul as Its Chief Medical Officer |
Official Site Inspections
http://www.anaptysbio.com Semrush global rank: 2.58 M Semrush visits lastest month: 6.81 K
Unable to get host informations!!!
More informations about "AnaptysBio"
AnaptysBio - Crunchbase Company Profile & Funding
AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease.See details»
About - AnaptysBio
Enable broad development of our best-in-class programs targeting co-inhibitory receptors in AD, RA, and UC, respectively.. Generate in vitro and in vivo translational and clinical data to inform …See details»
AnaptysBio - LinkedIn
AnaptysBio Biotechnology Research San Diego, California 9,943 followers Transforming patient health by delivering innovative immunology therapeutics.See details»
AnaptysBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology …See details»
AnaptysBio, Inc. (ANAB) Company Profile & Overview - Stock …
Jan 26, 2017 AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD …See details»
AnaptysBio, Inc. Company Profile | San Diego, CA | Competitors ...
Find company research, competitor information, contact details & financial data for AnaptysBio, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
AnaptysBio, Inc. (ANAB) Company Profile & Facts - Yahoo Finance
Description . AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD …See details»
AnaptysBio Company Profile - Office Locations, Competitors
Oct 29, 2024 AnaptysBio has 5 employees across 2 locations and $17.16 m in annual revenue in FY 2023. See insights on AnaptysBio including office locations, competitors, revenue, …See details»
AnaptysBio - Contacts, Employees, Board Members, Advisors
Organization. AnaptysBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 19. Number of Board …See details»
AnaptysBio Announces Second Quarter 2021 Financial Results and …
Jun 30, 2021 AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The …See details»
AnaptysBio, Inc. (ANAB) - Yahoo Finance Canada
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, …See details»
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive …
Nov 27, 2023 Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of …See details»
Anaptys Announces Second Quarter 2024 Financial
Jun 30, 2024 AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data) (unaudited) Three Months Ended June 30, Six Months …See details»
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth …
Nov 21, 2024 AnaptysBio’s stock is a neutral investment opportunity right now, in our opinion. On one hand, their focus on immune cell modulation and experienced management team …See details»
AnaptysBio Recognized in BioSpace’s 2023 Best Places to Work
BioSpace considers each organization’s merits with particular emphasis on culture, leadership, career growth and development opportunities and innovation. AnaptysBio is thrilled to have …See details»
Anaptys Named a BioSpace 2024 Best Places to Work Winner
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology …See details»
AnaptysBio, Inc. (ANAB) Stock Price, News, Quote & History
Find the latest AnaptysBio, Inc. (ANAB) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Anaptys Announces Third Quarter 2024 Financial Results and …
Nov 5, 2024 AnaptysBio, Inc. Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024. Top-line Phase 2b data anticipated for rosnilimab, …See details»
Anaptys Named a BioSpace 2024 Best Places to Work Winner
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology …See details»